Skip to main content

Table 2 Causes for switching antifibrotics in first-line treatment and causes for discontinuation of second-line antifibrotics

From: Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

First-line treatment (n = 37) [Pirfenidone (n = 29), Nintedanib (n = 8)] Second-line treatment (n = 37) Nintedanib (n = 29), Pirfenidone (n = 8)
Disease progression 17 (45.9%), [2, 15] Gastrointestinal side effects 4 (5.4%), [1, 3]
Gastrointestinal disorders 12 (32.4%), [3, 9] Rash 1 (2.7%), [1, 0]
Photosensitivity 2 (5.4%), [2, 0] Rash and dizziness 1 (2.7%), [0, 1]
Liver enzyme elevation 2 (5.4%), [1, 1] Dizziness 1 (2.7%), [1, 0]
Peripheral eosinophilia 1 (2.7%), [1, 0] Gastrointestinal perforation 1 (2.7%), [1, 0]
Lung cancer development 1 (2.7%), [1, 0]   
Vasospastic angina suspected 1 (2.7%), [0, 1]   
Patients’ will 1 (2.7%), [1, 0]